Design and analysis of multi-center clinical trials are my primary research interests. I am currently a Principal investigator for a randomized multi-center 'Clarifying the Optimal Application of SLT Therapy (COAST) trial. I also coordinate the Data Management and Statistics core for the CDC's network studies for ambulatory settings and the New Vaccine Surveillance Network (NVSN). The trial network has the recognition of influencing national and international influenza vaccine policy for the northern hemisphere vaccine.
1995 | University of Western Ontario, Canada | Post-Doctoral Training in Actuarial Statistics
1992 | University of Madras, India | Doctor of Philosophy, Statistics
1987 | University of Madras, India | Masters of Philosophy, Statistics
1986 | University of Madras, India | Masters of Science, Statistics
1984 | Presidency College, India | Bachelor's of Science, Statistics
- Young Statistician Award - Received an Award from International Statistical Institute, The Netherlands. Work on " Markov Sampling for finite populations".
My research focused on statistical and epidemiological investigations of large multicenter clinical trials. My current research interest is developing and applying statistical methodologies on (i) Primary Open-Angle Glaucoma, (ii) Vaccine Effectiveness of Seasonal Influenza, COVID-19, and Other Respiratory Virus Vaccines for the Prevention of acute illness in Ambulatory and inpatient Settings.
- Clarifying the Optimal Application of SLT (COAST) Trial. Role: Principal Investigator. Funding Agency: NIH-UG1EY031651. September 01, 2020 - August 31, 2027. https://inside.upmc.com/pitt-wvu-glaucoma-laser-treatment-trial/.
- US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19, and Other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings: Role: Co- Investigator and Epidemiology Data Center Lead. Funding Agency: CDC. October 01, 2022 - September 30, 2027.
- Enhanced Surveillance for New Vaccine Preventable Disease – The New Vaccine Surveillance Network (NVSN). Role: Co- Investigator and Epidemiology Data Center Lead. Funding Agency: CDC. September 01, 2021 - August 31, 2026.
- Burden of hMPV infections over 5 seasons: Role: Co-Investigator and Data Center Lead. Funding Agency: Icosavax, Inc., January 1, 2024 - December 31, 2024.
Complete List of Published Work in My Bibliography over 150 peer-reviewed publications.
- Tony Realini, Kevin Halenda, Joel Palko, G.K. Balasubramani. Test-Retest Reliability of Intraocular Pressure Measurements with Office-Based versus Home-Based Rebound Tonometers. Journal of Glaucoma. 2024 May 27. doi: 10.1097/IJG.0000000000002441. PMID: 38814353.
- Mary Patricia Nowalk, Rachel Taber, Todd M. Bear, Xueyan Zhang, Klancie Dauer, Theresa M. Sax, Michael Susick, Louise H. Taylor, Karen Clarke, Krissy Moehling Geffel, Richard K. Zimmerman, G.K. Balasubramani. Health-related Quality of Life following Mild COVID-19 Illness. American Journal of Health Behavior 2024, doi.org/10.5993/AJHB.48.2.6.
- Yachana Panchal, Jessica M. Gannon, Janina-Marie Tatar, G.K. Balasubramani. COVID-19 vaccination among patients with schizophrenia prescribed clozapine, Schizophrenia Research, November 2023, Volume 261, Pages 31-33. PMID: 37690168.
- Zimmerman RK, Patricia Nowalk M, Dauer K, Clarke L, Raviotta JM, G.K. Balasubramani. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design. Vaccine. 2023 Aug 7;41(35):5134-5140. Doi: 10.1016/j.Vaccine.2023.06.056. Epub 2023 Jul 18. PMID: 37474406.
- Mary Patricia Nowalk, Theresa M. Sax, Michael Susick, Louise H. Taylor, Lloyd G. Clarke, Klancie Dauer, Karen Clarke, Krissy Moehling Geffel, Richard K. Zimmerman, G.K. Balasubramani. Effect of mild COVID-19 on health-related quality of life. Brain, Behavior, & Immunity – Health. 2023, Vol. 28, doi.org/10.1016/ j.bbih. 2023.100596. PMID: 36713477.
- Zimmerman RK, Dauer K, Clarke L, Nowalk MP, Raviotta JM, G.K. Balasubramani. Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design. Human Vaccine and Immunotherapeutics. 2023 Dec 31;19(1):2177461. doi: 10.1080/21645515.2023.2177461. Epub 2023 Feb 21. PMID: 36809982; PMCID: PMC10026862.
- Mary Patricia Nowalk, Theresa M. Sax, Michael Susick, Louise H. Taylor, Lloyd G. Clarke, Klancie Dauer, Karen Clarke, Krissy Moehling Geffel, Richard K. Zimmerman, G.K. Balasubramani. Effect of mild COVID-19 on health-related quality of life. Brain, Behavior, & Immunity – Health. 2023, Vol. 28, doi.org/10.1016/ j.bbih. 2023.100596. PMID: 36713477.
- Zimmerman RK, Dauer K, Clarke L, Nowalk MP, Raviotta JM, G.K. Balasubramani. Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design. Human Vaccine and Immunotherapeutics. 2023 Dec 31;19(1):2177461. doi: 10.1080/ 21645515.2023.2177461. Epub 2023 Feb 21. PMID: 36809982
- G.K. BalasubramaniUsing capture-recapture methods to estimate influenza hospitalization incidence rates. Influenza Other Respiratory Viruses. 2022 Mar; 16(2): 308-315. doi: 10.1111/irv.12924. PMID: 34750974.
- G.K. Balasubramani, Nowalk MP, Eng H, Zimmerman RK.: Estimating the burden of adult hospitalized RSV infection using local and state data - methodology. Human Vaccines and Immunotherapeutics. 2022 Dec 31;18(1):1958610. doi: 10.1080/ 21645515.2021. 1958610.PMID: 35271432.
